← Research ProtocolsCagrilintide + Semaglutide
STUDIED EXPOSURE MAP / 2025
Cagrilintide + Semaglutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 3NEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
2.4 mg cagrilintide + 2.4 mg semaglutide
once weekly combination target exposure
Context: This page reports the studied combination target exposure. It does not imply that independently sourced compounds are equivalent to the trial combination compound.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2025
01 / DESIGNRandomized controlled phase-3 combination study
02 / POPULATION / MODELAdults with overweight or obesity
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAMELong-duration weight-management trial
05 / PRIMARY QUESTIONChange in body weight and related outcomes
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.